- Home
- / IGM Biosciences
IGM Biosciences
Stock Price
$17.3
2024-10-29
Market Capitalization
$1 B
2024-10-29
IGM Biosciences Summary
Company Summary
- Overview
- IGM Biosciences is a biotechnology company involved in the development of engineered antibodies for the treatment of cancer. It develops a proprietary IgM antibody technology platform aiming to improve the efficacy and safety of IgG antibodies in multiple therapeutic applications.
- Type
- Public
- Status
- Active
- Founded
- 2010
- HQ
- Mountain View, CA, US | view all locations
- Website
- http://igmbio.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Bruce Keyt, Chief Scientific Officer
Misbah Tahir, Chief Financial Officer
Suzette Tauber, Chief Human Resources Officer
Operating MetricsView all
Clinical Programs
3
Q2, 2019
Patents Issued
3
Q2, 2019
Patent Applications
45
Q2, 2019
LocationsView all
1 location detected
Mountain View, CA HQ
United States
325 E Middlefield Rd
IGM Biosciences Financials
Summary Financials
- Net income (Q2, 2025)
- $97.6M
- Cash (Q2, 2025)
- $30.6M
- EBIT (Q2, 2025)
- $96.3M